This article is more than 5 years old. Information may no longer be current.
Bayer submits European marketing application for VEGF agent
TARRYTOWN, N.Y. — Bayer HealthCare has submitted a marketing application in Europe for VEGF Trap-Eye for the treatment of wet age-related macular degeneration, Regeneron and Bayer announced in a joint press release.
The companies are promoting VEGF Trap-Eye (aflibercept ophthalmic solution) therapy in an effort to bring awareness to alternative treatments requiring fewer injections.
"The submission of VEGF Trap-Eye for EU marketing authorization represents a significant milestone in our goal to bring this potentially important new therapy to patients with wet AMD across the globe," Leonard S. Schleifer, MD, PhD, president and CEO of Regeneron said in the release.
The application submission followed two successful phase 3 trials, VIEW 1 and VIEW 2.
The 52-week trials found a greater number of patients treated with VEGF Trap-Eye who either gained or maintained vision in comparison to patients treated with ranibizumab. There were no substantial differences in nonocular adverse events among the study arms.
Bayer will be marketing VEGF Trap-Eye outside of the United States and will share profits equally with Regeneron.
Regeneron will maintain exclusive rights to market VEGF Trap-Eye in the U.S.